CompletedNot Applicable

TDCs to Treat Drug-resistant Epilepsy

United Kingdom100 participantsStarted 2017-01-01

Plain-language summary

Epilepsy is the fourth overall neurologic disorder, regardless of age and gender. It encompass a wide spectrum of conditions, intensities and seizure types; therefor, several drugs have proven to treat different types of seizures. However, around 22.5 % of patients are unable to attain control regardless of the drug used or even a combination of several of them. TDCs offers a non-invasive approach with a focal effect for those patients. The focus of this study is to define the role for tDCS in the treatment of drug-resistant epilepsy on children.

Who can participate

Age range18 Months – 120 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18-90 montths * Having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose. * At least 2-3 seizure per month documented with EEG, not only clinically. * In good health except epilepsy. * Patients or his(her) familys could understand this method and sign the informed consent 7）Patients with good compliance and could complete postoperative follow-up. Exclusion Criteria: * Results of MRI remind epilepsy caused by intracranial space-occupying lesions. * Tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental disease，pepticulcer，diabetes Type 1，bad health etc, and other surgical contraindication * sleep-related breathing disorders

What they're measuring

Decrease in number of crisis per day

Timeframe: 4 months

Body mass index

Timeframe: 4 Months

Trial details

NCT IDNCT05825274

SponsorSpanish Foundation for Neurometrics Development

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-10-01